retatrutide peptide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— Demand for Unapproved Weight-Loss Drug

Different mechanisms of action may elicit fewer GI adverse events, which are seen in ~40% of patients on semaglutide or tirzepatide

What Is GLP-1 and Why Does It Matter

Risks of kidney failure and death in a real-world population with diabetes

Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts

Cost, Insurance Coverage, and Access Public insurance coverage for GLP-1 obesity treatments is spotty in the United States

Glycemic control and insulin sensitivity For patients with type 2 diabetes or prediabetes, the HbA1c reduction from tirzepatide is substantial